<DOC>
	<DOCNO>NCT01559064</DOCNO>
	<brief_summary>This prospective , observational study volumizing effect aesthetic use Juvéderm VOLUMA® lidocaine mid-face area .</brief_summary>
	<brief_title>The Volumizing Effect Juvéderm VOLUMA® Mid-Face</brief_title>
	<detailed_description />
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Desire willingness correction asymmetry enhancement his/her midface area . Be willing undergo treatment volume loss face area Females males ≥30 year age Be good health opinion Investigator Sign Informed Consent Form prior studyrelated procedure perform Have establish realistic treatment goal Investigator agree achievable i.e. , realistic expectation aesthetic result Have extensive tissue damage could affect aesthetic outcome Have know allergy component VOLUMA® lidocaine injection Have abscess infection time treatment opinion Investigator make subject eligible procedure . Have undergone cosmetic facial [ e.g. , facelift , surgery , may alter appearance midface region ( laser , photomodulation intense pulse light , radio frequency , dermabrasion , moderate great depth chemical peel , ablative procedure ) , tissue augmentation dermal filler fat injection , mesotherapy ] anywhere midface region , Botox® Cosmetic injection low face ( orbital rim ) , within 6 month prior entry study planning undergo procedure time study . NOTE : Prior treatment hyaluronic acid ( HA ) filler and/or collagen allow , provide treatment administer 6 month prior study entry Have ever receive semipermanent filler permanent facial implant , e.g. , calcium hydroxyapatite , Lpolylactic acid , polymethylmethacrylate ( PMMA ) , silicone , expand polytetrafluoroethylene ( ePTFE ) anywhere lips , plan implant product time study Have history anaphylaxis , multiple severe allergy , atopy , allergy lidocaine ( amidebased anesthetic ) , HA product , Streptococcal protein , plan undergo desensitization therapy term study Suffer uncontrolled personality disorder ( e.g. , body dysmorphia , depression ) Have history currently suffer autoimmune disease ( e.g. , Rheumatoid arthritis , Crohn 's disease ) Have history streptococcal disease ( e.g. , strep throat rheumatic fever without heart complication ) Have history skin cancer Suffer Porphyria Have epilepsy control antiepilepsy therapy Current cutaneous inflammatory and/or infectious process ( e.g. , acne , herpes , etc . ) Have history treatment interferon therapy ( e.g. , warfarin ) take nonsteroidal antiinflammatory drug ( NSAIDs ) ( e.g. , aspirin , ibuprofen ) substances known increase coagulation time ( e.g. , herbal supplement garlic ginko biloba ) within 10 day undergo study device injection . NOTE : Study device injection may delay necessary accommodate 10day washout period Be concurrent regimen high dos lidocaine ( 400 mg ) may cause acute toxic reaction Be concurrent regimen local anesthetic structurally relate amidetype local anesthetic Have impair cardiac conduction , severly impaired hepatic function , severe renal dysfunction Have condition situation , Investigator 's opinion , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>